Brookline Capital Management Forecasts MRKR FY2024 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Stock analysts at Brookline Capital Management issued their FY2024 earnings estimates for shares of Marker Therapeutics in a research note issued to investors on Monday, February 10th. Brookline Capital Management analyst L. Cann expects that the company will post earnings per share of ($0.25) for the year. Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.05) per share.

Separately, LADENBURG THALM/SH SH boosted their target price on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a report on Monday, October 21st.

Marker Therapeutics Trading Up 2.6 %

Shares of NASDAQ:MRKR opened at $1.59 on Thursday. Marker Therapeutics has a 12-month low of $1.48 and a 12-month high of $5.99. The business’s fifty day simple moving average is $2.88 and its 200-day simple moving average is $3.24.

Hedge Funds Weigh In On Marker Therapeutics

Several institutional investors have recently made changes to their positions in MRKR. Invst LLC acquired a new stake in Marker Therapeutics during the third quarter valued at $56,000. LPL Financial LLC purchased a new stake in shares of Marker Therapeutics during the 4th quarter worth about $248,000. Finally, Aisling Capital Management LP boosted its stake in shares of Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock worth $1,012,000 after acquiring an additional 11,084 shares in the last quarter. 22.39% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Enterprise Associates 16 New bought 554,250 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the acquisition, the insider now directly owns 1,625,678 shares of the company’s stock, valued at $5,202,169.60. This trade represents a 51.73 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steve Elms bought 11,085 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now owns 325,370 shares of the company’s stock, valued at $1,041,184. The trade was a 3.53 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 17.35% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.